Release Date: December 22, 2025
Expiration Date: December 22, 2026
Activity Overview
This session of the 2025 International Symposium of Gastrointestinal Oncology (ISGIO) focused on the management of pancreatic adenocarcinoma and GI neuroendocrine tumors. The expert faculty provided updates on special topics in pancreatic cancer, including neoadjuvant therapy for resectable disease and the use of metastasis-directed therapy in oligometastatic pancreatic cancer.
This was followed by lectures on current and emerging systemic therapy landscapes for pancreatic and neuroendocrine tumors. The session concluded with a case presentation and lecture on emerging molecular biomarkers for potentially curable neuroendocrine tumors.
Registration is
also now open for ISGIO 2026, taking place October 2-3, 2026, in Ft
Lauderdale, Florida. Click here to learn more.
Target Audience
This educational activity is directed toward medical oncologists and practitioners of oncology subspecialties, surgeons, radiologists, general scientists, young investigators, nurses, and pharmacists with an interest in GI oncology. Other health care professionals interested in the treatment of these malignancies are also invited to participate.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Incorporate biomarker testing results to individualize treatment selection for patients with GI cancers
- Incorporate novel data to effectively sequence available therapies for optimal outcomes in patients with GI cancers
Laura Dawson, MD, FRCPC, FASTRO
Professor and Chair
Department of Radiation Oncology
University of Toronto
Radiation Oncologist, Radiation Medicine Program
Princess Margaret Cancer Centre, University Health Network
Toronto, Ontario, Canada
Disclosures: Grant/Research Funding: Elekta, Merck; Consultant: AstraZeneca, Elekta
Thorvardur R. Halfdanarson, MD
Professor of Oncology
Consultant, Division of Medical Oncology
Mayo Clinic
Rochester, MN
Disclosures: Grant/Research Funding: Advanced Accelerator Applications (a Novartis company), Camurus, Crinetics, ITM Isotopen Technologien Muenchen, Perspective Therapeutics, Rezolute, Thermo Fisher Scientific; Consultant: Abdera Therapeutics, Boehringer Ingelheim, Camurus, Crinetics, Curium, Exelixis, Ipsen, ITM Isotopen Technologien Muenchen, Novartis, Perspective Therapeutics, TerSera
Eileen M. O’Reilly, MD, FASCO
Winthrop Rockefeller Endowed Chair in Medical Oncology
Section Head, Hepatopancreaticobiliary & Neuroendocrine
Cancers
Chair, Human Research Protection Program & IRB
Co-Director Medical, David M. Rubenstein Center for Pancreatic
Cancer
Attending Physician, Member
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, NY
Disclosures: Research: AbbVie, Agenus, Arcus, AstraZeneca, Atara, BeiGene, BioNTech, Bristol Myers Squibb, Coherus, Digestive Care, Elicio, Genentech/Roche, Helsinn, J-Pharma, Parker Institute, Pertyze, Yiviva; Consulting: AbbVie, Ability Pharma, Agenus, Alligator Bioscience, Astellas, Arcus, AstraZeneca, Autem, Berry Genomics, BioNTech, Boehringer Ingelheim, Bristol Myers Squibb, FibroGen, Genentech/Roche, Ipsen, J-Pharma, Merck, Merus, MOMA Therapeutics, Neogene, Novartis, Regeneron, Revolution Medicines, Servier, Syros, Tango, Tempus, Vector, Yiviva
Scott Paulson, MD
Director of Clinical Research
Texas Oncology
Medical Director, Neuroendocrine Research and Treatment Center
Texas Oncology–Baylor Charles A. Sammons Cancer Center
Dallas, TX
Disclosures: Advisor/Consultant/Speaker/Honoraria Recipient: Agenus, Amgen, Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Exelixis, IDEOlogy Health, Jazz Pharmaceuticals, Johnson & Johnson, Lilly Pharmaceuticals, Mirati, Novartis, Pfizer, Takeda; Grant/Research Funding: AbbVie, AstraZeneca, Bayer, BioNTech SE, Bristol Myers Squibb, Camurus, Exelixis, Gritstone Bio, HUTCHMED, Inspirna, Ipsen, ITM Oncologics, Johnson & Johnson, Lilly, Merck, Novartis, Pfizer, Revolution Medicines, SOTIO, Taiho, Tempus, TransThera Biosciences; Other: Family member works for Lilly
Omair A. Shariq, MD, PhD
Y1 Fellow Department of Surgery
Mayo Clinic
Rochester, MN
Disclosures: Omair A. Shariq, MD, PhD, has no relevant financial relationships with ineligible companies.
Aatur D. Singhi, MD, PhD
Associate Professor of Pathology
Giant Eagle Endowed Chair for Cancer Genetics
Vice Chair and Chief of the Division of Translational Pathology
Co-Director, Pancreatic Cancer Research at UPMC Hillman Cancer Center
University of Pittsburgh Medical Center
Pittsburgh, PA
Disclosures: Aatur D. Singhi, MD, PhD, has no relevant financial relationships with ineligible companies.
Alice C. Wei, MD, CM, MSc, FRCSC, FACS
Attending Surgeon, Hepatopancreatobiliary Service
Department of Surgery
Co-Director of Surgical Initiatives, David M. Rubenstein Center
for
Pancreatic Cancer Research
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosures: Advisor/Consultant/Speaker/Honoraria Recipient: HistoSonics; Grant/Research Funding: Ipsen
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
